Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$48.96M

FY 2025 · Annual

Investing Cash Flow

-$26.94M

FY 2025 · Annual

Financing Cash Flow

$88.33M

FY 2025 · Annual

+202.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Depreciation & Amortization181K222K287K308K327K
Deferred Income Tax288K0000
Stock-Based Compensation302K3.41M7.63M10.62M11.98M
Change in Working Capital2.6M(451K)(3.31M)(765K)(10.37M)
Accounts Receivables47K25K(3K)22K(3K)
Inventory1K(208K)131K(28K)(137K)
Accounts Payables1.08M0145K2.97M0
Other Working Capital1.47M(268K)(3.58M)(3.73M)(10.23M)
Other Non-Cash Items217K1.14M(1.61M)308K1.81M
Operating Cash Flow(19.43M)(29.29M)(46.13M)(50.56M)(48.96M)
Capital Expenditures(274K)(591K)(78K)(289K)(489K)
Acquisitions (Net)(13.29M)00(602K)0
Purchases of Investments(213K)(63.53M)(142.03M)(72.65M)(76.31M)
Sales of Investments13.5M0152.8M86.63M49.86M
Other Investing Activities13.29M0000
Investing Cash Flow13.02M(64.12M)10.69M13.09M(26.94M)
Debt Repayment(4M)3.55M(10.85M)15M17.91M
Common Stock Issued7K109.83M254K15.04M71.97M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7K(10.13M)56.81M(864K)(1.55M)
Financing Cash Flow(3.99M)103.26M46.22M29.17M88.33M
Effect of Forex Changes00000
Net Change in Cash(10.41M)9.85M10.78M(8.3M)12.43M
Free Cash Flow(19.7M)(29.88M)(46.21M)(50.85M)(49.45M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$52.7M
+ D&A$327.0K
+ Stock-Based Comp$12.0M
+ Deferred Tax$0
- Working Capital-$10.4M
+ Other Non-Cash$1.8M
= Operating Cash Flow-$49.0M
- Capex-$489.0K
= Free Cash Flow-$49.5M

Analysis

FY2025 free cash flow is -$49.5M. FCF conversion is 93.8% of net income. Operating cash flow was -$49.0M, with capex of -$489.0K. The largest bridge item is Stock-Based Comp at $12.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
SC 13D/ASC 13D/A filingNov 12, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipNov 9, 2026
4Statement of changes in beneficial ownershipNov 9, 2026

Does OBIO generate free cash flow?

Orchestra BioMed Holdings, Inc. (OBIO) generated -$49.45M of free cash flow in fiscal 2025.

How much operating cash flow does OBIO produce?

Operating cash flow was -$48.96M, before capital expenditures of $489,000.00.